Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Epstein

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Hypertension (Dallas, Tex. : 1979)|September 8, 2016
Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) EraRaymond R Townsend, Murray Epstein
The Medical Clinics of North America|February 12, 2004
Evolving role of calcium antagonists in the management of hypertensionMurray Epstein, Vito M Campese
Nature Reviews. Nephrology|February 22, 2012
Statins in the management of dyslipidemia associated with chronic kidney diseaseMurray Epstein, Nosratola D Vaziri
The American Journal of Medicine|February 23, 2016
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016Murray Epstein, Daniel A Duprez
European Heart Journal|June 30, 2016
A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden fruit'Murray Epstein, Bertram C Pitt
Nephrology News & Issues|June 4, 2016
Arrhythmias and sudden cardiac death in hemodialysis patients. Temporal profile, electrolyte abnormalities, and potential targeted therapiesMurray Epstein, Prabir Roy-Chaudhury
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 8, 2005
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal functionMurray Epstein, Vito M Campese
Kidney International Supplements|March 23, 2022
The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targetsMorley D Hollenberg, Murray Epstein
Kidney International Reports|November 17, 2017
The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical TrialsMurray Epstein, Meyer D Lifschitz
Hypertension (Dallas, Tex. : 1979)|April 12, 2006
Aldosterone and large artery vesselsMurray Epstein, Michel E Safar
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Hypertension (Dallas, Tex. : 1979)|September 8, 2016
Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) EraRaymond R Townsend, Murray Epstein
The Medical Clinics of North America|February 12, 2004
Evolving role of calcium antagonists in the management of hypertensionMurray Epstein, Vito M Campese
Nature Reviews. Nephrology|February 22, 2012
Statins in the management of dyslipidemia associated with chronic kidney diseaseMurray Epstein, Nosratola D Vaziri
The American Journal of Medicine|February 23, 2016
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016Murray Epstein, Daniel A Duprez
European Heart Journal|June 30, 2016
A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden fruit'Murray Epstein, Bertram C Pitt
Nephrology News & Issues|June 4, 2016
Arrhythmias and sudden cardiac death in hemodialysis patients. Temporal profile, electrolyte abnormalities, and potential targeted therapiesMurray Epstein, Prabir Roy-Chaudhury
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 8, 2005
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal functionMurray Epstein, Vito M Campese
Kidney International Supplements|March 23, 2022
The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targetsMorley D Hollenberg, Murray Epstein
Kidney International Reports|November 17, 2017
The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical TrialsMurray Epstein, Meyer D Lifschitz
Hypertension (Dallas, Tex. : 1979)|April 12, 2006
Aldosterone and large artery vesselsMurray Epstein, Michel E Safar
Pageof 8